Citations

Clear

1446 citation(s) found for "Howard, F".

Hematological symptom burden and treatment patterns in patients with IgG4-related disease: A real-world, multicenter retrospective analysis
Vojjala, Nikhil, Gillani, Syed Fahad, Shah, Rushi, Kotla, Nikhil Kumar, Mahadevia, Himil, Valasapalli, Srijan, Krishnamoorthy, Geetha, Singh, Vijendra, Vojjala, Nikhil, Gillani, Syed Fahad, Shah, Rushi, Kotla, Nikhil Kumar, Mahadevia, Himil, Valasapalli, Srijan, Krishnamoorthy, Geetha, Singh, Vijendra

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4479-4479

10.1182/blood-2025-4479 Get It

Abstract Background: IgG4-related disease (IgG4-RD) is a rare, immune-mediated fibroinflammatory condition characterized by tissue infiltration with IgG4-positive plasma cells. While solid organ involvement is well documented, data on hematologic manifestations and associated outcomes remain limited. Understanding hematological burden and real-world treatment patterns is essential to guide comprehensive management. Methods: We conducted a multicenter, retrospective cohort study using the TriNetX Research Network, comprising electronic health records from multiple U.S. healthcare systems. Adults (≥18 years) with a diagnosis of IgG4-RD (ICD-10 codes) were included. Patients with a prior diagnosis of hematologic malignancy were excluded. Demographic characteristics, hematologic manifestations, treatment patterns, and overall mortality were assessed. The median follow-up duration was 519 days. Results: A total of 2,596 patients with IgG4-RD were identified, of whom 554 (21.3%) exhibited at least one hematologic manifestation. The mean age was 58.1 ± 15.9 years; 53% were male (n=1,379), and 57% were White (n=1,492). Hypertension was the most common comorbidity (44%, n=1,136). Among those with hematologic involvement, key manifestations included lymphadenopathy (n=605, 23.3%), hepatomegaly (n=114, 4.4%), splenomegaly (n=73, 2.8%), eosinophilia (n=71, 2.7%), pancytopenia (n=31, 1.2%), hypergammaglobulinemia (n=71, 2.7%), and monoclonal gammopathy (n=86, 3.3%). Regarding outcomes, 127 of 2,596 patients (4.9%) died during the follow-up period. Among those with hematologic manifestations, 36 of 554 (6.5%) died, indicating a numerically higher mortality rate in this subgroup. Treatment data revealed that all patients received corticosteroids as initial therapy. Additionally, 531 patients (20.4%) received steroid-sparing immunosuppressants. The most used agents included rituximab (6%), azathioprine (6%), mycophenolate mofetil (5%), and methotrexate (3%). Conclusion: In this large, real-world cohort of patients with IgG4-RD, hematologic manifestations were observed in over one-fifth of patients and were associated with a numerically higher mortality rate. Lymphadenopathy was the most common hematologic feature. Despite the widespread use of corticosteroids, a substantial proportion of patients required steroid-sparing agents. These findings highlight the hematologic complexity of IgG4-RD and underscore the need for multidisciplinary management and prospective studies focused on hematologic outcomes.
Real-world comparison of thrombotic events in patients with Myelodysplastic Syndromes treated with luspatercept versus erythropoietin-stimulating agents using trinetx database
Gillani, Syed A , Shah, Raj, Agrawal, Shubham , Singh, Vijendra K. , Vojjala, Nikhil , Gillani, Syed Fahad, Mahadevia, Himil , Vegivinti, Charan Thej Reddy , Singh, Vijendra

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 22-22

10.1182/blood-2025-22 Get It

Abstract Background: Luspatercept, an erythroid maturation agent, has shown efficacy in improving anemia in both β-thalassemia and lower-risk myelodysplastic syndromes (MDS). In the BELIEVE trial, which led to its approval in transfusion-dependent β-thalassemia, thromboembolic events were notably higher in patients with risk factors such as splenectomy. More recently, the COMMANDS trial demonstrated superior transfusion independence with luspatercept over erythropoiesis-stimulating agents (ESAs) in ESA-naive, lower-risk MDS patients. However, limited data exist regarding comparative thrombotic risk in real-world MDS populations. We conducted a multicenter, real-world study to evaluate thrombotic event rates associated with luspatercept versus ESAs in MDS patients without prior venous thromboembolism (VTE). Methods: We queried the TriNetX Research Network, a federated real-time electronic health record (EHR) database covering over 100 million patients across major healthcare organizations. Adults (≥18 years) with a diagnosis of MDS (ICD-10-CM code D46) and no prior history of deep vein thrombosis (DVT) or pulmonary embolism (PE) were included. Patients were stratified based on treatment with luspatercept or ESAs (epoetin alfa or darbepoetin alfa). Propensity score matching (PSM) using a 1:1 nearest-neighbor algorithm without replacement was performed to balance demographics and clinical covariates. Primary outcomes included the incidence of DVT, PE, and composite VTE events within 12 months of therapy initiation. Results: A total of 6,448 patients with MDS and no prior VTE were identified: 5,698 received ESAs and 750 received luspatercept. The overall mean age was 72.5 ± 13.5 years, with 48.1% male. After PSM, 741 patients were included in each treatment arm. The matched cohort had a mean age of 76.7 ± 10.7 years, and 41.3% were female. In the ESA group, 58/741 (7.8%) developed DVT compared to 27/741 (3.6%) in the luspatercept group (Hazard Ratio [HR] 1.4; 95% CI, 0.9–2.3). PE occurred in 27 ESA-treated patients (3.6%) versus 13 luspatercept-treated patients (1.8%) (HR 1.3; 95% CI, 0.6–2.7; p=0.941). The overall composite VTE rate was 10.0% (74/741) in the ESA group and 4.9% (36/741) in the luspatercept group (HR 1.3; 95% CI, 0.9–2.0; p=0.732). Conclusion: In this large, multicenter real-world analysis, we observed a numerically lower incidence of thrombotic events with luspatercept compared to erythropoietin-based agents in patients with MDS, though differences did not reach statistical significance. These findings support the thrombotic safety profile of luspatercept observed in clinical trials and warrant further prospective validation.
ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states
Barredo, Bianca, Patnaik, Mrinal M. , Li, Peng , Vagher, Jennie , Pelletier, Sarah, Oster, Howard S. , Goldschmidt, Noa, Sinai, Anat, Basood, May, Trottier, Amy M. , Andreossi, Gloria, Heinrich, Michael , Brewer, Diana, Shoger, Kyle, Fonseca, Gustavo , Fiala, Elise , Birsoy-Ceyhan, Ozge, Offit, Kenneth , McGuinness, Molly , Drazer, Michael W. , Satty, Alexandra , Vlachos, Adrianna , Churpek, Jane , Drazer, Michael , Banaszak, Lauren Gabriele , Włodarski, Marcin W. , Lewis, Sara, Ferrer, Alejandro , Fox, Lucy C. , Osman, Afaf E.G. , DiNardo, Courtney D. , Stewart, Brittany, Carraway, Hetty E. , Mittelman, Moshe , Santini, Valeria , Druker, Brian J , Smith-Simmer, Kelcy J. , Kemel, Yelena , Mandelker, Diana L. , Marderstein, Andrew R. , Stadler, Zsofia , Cantor, Alan B , Bledsoe, Jacob R. , Homan, Claire C. , Brown, Anna

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1440-1440

10.1182/blood-2025-1440 Get It

Abstract Introduction Heterozygous germline pathogenic variants (PVs) in the 5' untranslated region of ANKRD26 cause inherited thrombocytopenia and predisposition to hematologic malignancy (HM). The estimated lifetime HM risk is ~10% based on families ascertained from an inherited thrombocytopenia cohort. However, the malignancy spectrum, molecular features, precursor states, and overall clinical outcomes remain poorly defined. Methods We established an international, multicenter cohort of individuals with ANKRD26-related thrombocytopenia diagnosed after undergoing genetic evaluation due to a personal and/or family history of thrombocytopenia and/or HM. Clinical, pathologic, and molecular data were collected for 27 individuals with germline ANKRD26 PVs from 21 unrelated families treated at 11 institutions across 5 countries. Statistical analyses were performed using R (v4.4.2). Results Patients were predominantly male (18/27) and white (25/27). Thrombocytopenia was typically identified in childhood (median age 10 years, range 0-48) with a genetic diagnosis made later (median age 53 years, range 2-80). The mean (+/- SD) pre-malignancy platelet count was 45 +/- 24 K/uL (range 5-87). ANKRD26 PVs observed in each family included: c.-126T>C (n=9), c.-128G>A (n=3), c.-134G>A (n=3), c.-116C>T (n=3), c.-118C>T (n=2), and c.-118C>A (n=1). Thirteen HMs were diagnosed in 11 of 27 (41%) patients, including myelodysplastic neoplasm/syndrome (MDS, n=5), acute myeloid leukemia (AML, n=3), chronic myeloid leukemia (CML, n=2), MDS/myeloproliferative neoplasm (MPN) overlap (n=2), and Langerhans cell histiocytosis (n=1). The median age at first HM diagnosis was 63 years (range 49-80). Recurrent somatic features in myeloid malignancies included complex karyotype (4/11, 36%) and TP53 mutations (5/10, 50%). Of the 3 patients with AML, 1 achieved a partial remission (PR) with venetoclax combined with cladribine, idarubicin, and cytarabine but relapsed, 1 achieved a PR with azacitidine but relapsed <100 days after haploidentical allogeneic stem cell transplantation (alloSCT), and 1 had primary refractory disease. Among 5 patients with MDS, 1 was refractory to decitabine, 1 underwent alloSCT but relapsed 2 years post-transplant, 1 remains in remission post-alloSCT with 1 year of follow-up, 1 is undergoing alloSCT evaluation, and 1 was lost to follow-up. Both patients with CML achieved durable major molecular remissions with imatinib. To better estimate HM risk, we assumed 100% penetrance of thrombocytopenia for ANKRD26 PV carriers and included family members with chronic thrombocytopenia who had not had germline genetic testing. In this expanded series (n=62), 16 individuals developed a HM (26%). Additional diagnoses included MDS with progression to AML (n=1), AML (n=1), CML (n=1), and leukemia of unknown type (n=2). Cumulative incidence of HM was 0% by age 40 years, 17% by age 60 years, and 60% by age 80 years. Somatic sequencing of peripheral blood was performed in 5 HM-unaffected ANKRD26 PV carriers. One individual was found to have clonal hematopoiesis driven by TET2 (c.1648C>T, p.Arg550*) with a variant allele frequency (VAF) of 9% at age 55. Bone marrow biopsy showed mild megakaryocytic atypia and 4% blasts without overt evidence of malignancy. To assess the prevalence of ANKRD26-related HM, we assessed the frequency of ANKRD26 PVs in 2 large MDS/AML cohorts. In the ARUP database (9662 AML, 6397 MDS), 2 individuals (0.01%) had an ANKRD26 PV with a VAF consistent with germline origin. In the MSK-IMPACT Heme Germline MDS/AML cohort (n = 284), no ANKRD26 P/LP variants were identified. Conclusions Germline ANKRD26 PVs underlie <1% of MDS/AML diagnoses but may represent a high-risk subtype characterized by complex karyotype, TP53 mutations, and high risk of relapse. Among our series, the incidence of HM was low early in life but increased substantially with age, reaching 60% by 80 years. This exceeds prior estimates, which were derived from individuals ascertained from thrombocytopenia-based registries. Together, our findings suggest that ANKRD26-associated HM may represent a high-risk clinical entity, and that age and family history should inform surveillance strategies. More studies are needed to define genetic and environmental modifiers of HM risk as well as precursor states to enable early detection and disease interception.
Prognostic value of 18F-FDG PET/CT volumetric parameters in childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL): a systematic review from the international SEARCH group (Staging, Evaluation and Response Criteria Harmonization)
Castellino, S, Dieckmann, Karin, Kelly, Kara M. , Kurch, Lars , Lai, Hollie , Mauz-Koerholz, Christine, McCarten, Kathleen M. , Steglich, J., Stoevesandt, Dietrich, Voss, Stephan D. , Milgrom, Sarah A. , Gowdy, Claire , Flerlage, Jamie E. , Seelisch, Jennifer , Palese, M, Bradshaw, Tyler , Castellino, Sharon M. , Cho, Steve K. , Hoppe, Bradford S. , Howard, Scott C. , Lopci, Egesta , Lucas, John T. , Mauz‐Körholz, Christine , Pandit-Taskar, Neeta D. , Schöder, Heiko

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812922 Get It

Abstract 245: Super‐Large‐Bore vs Large‐Bore Aspiration Catheters in Mechanical Thrombectomy: A Multicenter Propensity‐Matched Analysis
Chacon, Alexander , Inoa, Violiza , Cawley, M. F., Rai, Ansaar , Maier, Ilko , Dye, J. A., Ezzeldin, M., Matouk, Charles, Brinjikji, Waleed , Jabbour, Pascal , Almallouhi, E., Dağlıoğlu, Ergün , Spiotta, Alejandro M , Grossberg, Jonathan A , Chacon, A., Alawieh, Ali , Motiwala, Mustafa , Arthur, Adam Stephen , Cawley, M., Howard, Brian M , Siddiqui, F., Alaraj, Ali , Romano, Daniele Giuseppe , Fiorella, David , Dye, J., Wolfe, Stacey Q , Mascitelli, Justin R , Fragata, Isabel , Limaye, Kaustubh , Ogilvy, Christopher S. , Jabbour, Pascal , Almallouhi, Eyad , Park, M. S., Navía, Pedro , Grandhi, Ramesh , Altschul, David , Schirmer, Clemens M. , Paul, Alexandra R , Mokin, Maxim , Goyal, Nitin

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_245 Get It

Background Contact aspiration remains a frontline approach for mechanical thrombectomy (MT) in acute ischemic stroke (AIS). Early evidence correlates catheter size with procedural efficiency and clinical outcomes. Larger‐bore (LB) aspiration catheters may enhance clot ingestion, increase aspiration force, and facilitate faster and more complete recanalization. However, the transition from standard LB catheters (0.068‐0.072″) to super‐large‐bore (SLB, ≥0.080″) devices has raised questions regarding both safety and clinical benefit. Although the use of SLB catheters is increasing, comparative data on their performance versus LB catheters remain limited. This study aims to evaluate the safety and efficacy of SLB compared with LB catheters including data from a large multicenter international registry. Methods We retrospectively analyzed patients with AIS due to LVO treated at 46 international stroke centers between January 2013 and June 2025. Among eligible patients, propensity score matching (PSM) at a 5:1 ratio was used to balance baseline characteristics between those treated with standard LB catheters and those treated with SLB catheters. Safety endpoints included intraprocedural complications, symptomatic intracranial hemorrhage (sICH), distal embolization, and 90‐day mortality. Efficacy endpoints included functional independence at 90 days (modified Rankin Scale [mRS] 0‐2), successful recanalization (TICI ≥2b), first‐pass effect (TICI ≥2b on the first aspiration attempt), and procedural timing to TICI2b. Results A total of 3,100 patients were included (LB n=3,024; SLB n=67). After PSM (LB n=335; SLB n=67), safety outcomes were comparable between groups in terms of intraprocedural complications occurred (p=0.5), sICH (p>0.9), embolization to new territory (p=0.2), and 90‐day mortality (p>0.9). Efficacy outcomes were similarly consistent for functional independence (mRS 0‐2) (p>0.9), successful recanalization (p>0.9), first‐pass effect (p=0.5), and time to TICI ≥2b (27.6 vs. 24.5 minutes; p=0.9). These findings remained consistent in the subgroup with ICA and M1 occlusions, with no significant differences in safety (intraprocedural complications [p=0.4], sICH [p>0.9], embolization to new territory [p=0.6], or 90‐day mortality [p>0.9], nor in efficacy outcomes (functional independence at 90 days [p>0.9], successful recanalization [p=0.9], first‐pass effect [p=0.6], and time to TICI ≥2b [p=0.9]). Conclusion In this large multicenter analysis, the use of SLB aspiration catheters demonstrated comparable safety and efficacy to standard LB catheters for MT in AIS. Despite theoretical advantages in aspiration dynamics, SLB devices did not confer significant procedural or clinical benefit over LB catheters. These findings suggest that while SLB catheters are a feasible alternative, technical and clinical outcomes remain comparable to LB catheters. Further prospective studies are warranted to clarify potential clinical advantages. image
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Walbert, Tobias , Lassman, Andrew B. , Peereboom, David M. , Kizilbash, Sani H. , Matsuoka, Carlos Kamiya , Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Butowski, Nicholas , Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Wang, Chao , Levin, Victor A. , Lassman, Andrew B , Peereboom, David M , Kizilbash, Sani H , Kamiya-Matsuoka, Carlos , Pitz, Marshall W , Strowd, Roy E , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Soffietti, Riccardo , Butowski, Nicholas A , Forsyth, Peter A , Hamza, Mohamed A , Hau, Peter , Nabors, Louis Burt , Uhlmann, Erik J , Welsh, Liam C , Wen, Patrick Yung , Dietrich, Jorg , Wang, Chao , Levin, Victor A , Colman, Howard , Eoli, Marica , Strowd, Roy E. , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Lombardi, G

Mayo Clinic

Journal of Clinical Oncology | December 1, 2025 | Volume: 44 | Issue: 8 | Pages: 641-652

10.1200/jco-25-01204 | PMID 41325560 Get It

PURPOSE STELLAR (ClinicalTrials.gov identifier: NCT02796261 ) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase ( IDH ) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m 2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m 2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m 2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH- mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH -mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
Adopting Race‐Free Estimated Glomerular Filtration Rate for Unifying Medication‐Related Decision‐Making: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy
Wallace, J. , Rungkitwattanakul, Dhakrit , Khan, Rachel W. , Anderson, Lauren , Anderson, Erica , Nekidy, Wasim S. El , Nemecek, Branden D. , Meaney, Calvin J. , Prasad‐Reddy, Lalita , Salama, Lavinia , Hudson, Joanna Q. , Kane‐Gill, Sandra L. , Frazee, Erin N. , Anderson, Erica R , El Nekidy, Wasim S , Frazee, Erin N , Bzowyckyj, Andrew S , Kane-Gill, Sandra L , Peter, Wendy L. St.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | November 27, 2025 | Volume: 9 | Issue: 2 | Pages: No page available

10.1002/jac5.70153 | PMID 42009503 Get It

ABSTRACT Pharmacists play a critical role in optimizing medication use, especially in vulnerable populations such as those with chronic kidney disease (CKD). Despite strong evidence and recent guideline endorsements, many pharmacists continue to rely on the Cockcroft–Gault (C‐G) equation for medication dosing. This opinion paper issues a call to action for the widespread adoption of a race‐free, body surface area–adjusted estimated glomerular filtration rate (eGFR BSAadj ) for medication‐related decision‐making, as endorsed by the 2024 Kidney Disease: Improving Global Outcomes CKD guidelines and the National Kidney Foundation and the American Society of Nephrology Taskforce. Persistent variability in pharmacy practice, institutional protocols, and pharmacy education underscores the need for coordinated change. We urge health systems to integrate eGFR BSAadj into electronic health records and clinical decision support to enhance medication decision‐making; institutions to align protocols with contemporary eGFR‐based prescribing standards; pharmacy educators to contemporize and standardize education on kidney function assessment and medication dosing; and regulatory bodies to update licensure and board examinations. The pharmacy profession must act decisively in order to align with evidence‐based, equitable kidney‐related dosing practices and ensure optimal medication management for all patients.
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer
Nabid, Abdenour , Zapatero, Almudena, Bolla, M. , Joseph, David , Guerrero, A., Gonzalez, A. Alvarez, Segundo, Carmen González‐San , Rodríguez, María Ángeles Cabeza, Olivé, Agustí Pedro, Steigler, Allison , Souhami, Luís, Carrier, Nathalie , Armstrong, John G., Gillham, Charles, Pisansky, Thomas M. , Schipper, Matthew J. , Sandler, Howard M., Lawton, C.A., Roy, Soumyajit , Malone, Shawn , Hall, William A. , Shoag, Jonathan E. , Vince, Randy , García, Jorge A. , Mendiratta, Prateek, Valle, Luca , Dess, Robert T. , Jia, Angela Y. , Steinberg, Michael L. , Romero, Tahmineh , Kishan, Amar U. , Dess, Robert T , Zaorsky, Nicholas G. , Sun, Yilun , Zapatero, A. , Maingon, Philippe , Gonzalez San-Segundo, Carmen , Sole, Josep Maria, Efstathiou, Jason A. , Reijke, Theo M. de , Attard, Gerhardt , Morgan, Scott C. , Nguyen, Paul L. , Calaway, Adam , Barata, Pedro C. , Brown, Jason R. , Rettig, Matthew B. , Jackson, Will , Martin, Ting , Spratt, Daniel E.

Mayo Clinic

JAMA Oncology | November 20, 2025 | Volume: 12 | Issue: 1 | Pages: 58

10.1001/jamaoncol.2025.4800 | PMID 41264309 Get It

Importance The ideal duration of androgen deprivation therapy (ADT) for treating localized prostate cancer is unknown due to variable adherence and treatment durations tested in clinical trials. Objective To determine the ideal duration of ADT for patients with prostate cancer treated with radiotherapy. Data Sources This individual patient data meta-analysis of 13 randomized phase 3 clinical trials evaluated the use of radiotherapy alone or with ADT. It included patients with a median follow-up of 11.3 (IQR, 9.5-14.5) years and ADT duration of 0 to 36 months. Most patients (7392 [72%]) included had National Comprehensive Cancer Network high-risk or very high-risk disease. Study Selection For this meta-analysis, a systematic literature search from 1980 to 2020 was performed in trial registries (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov), MEDLINE (1966-2020), Embase (1982-2020), Web of Science, and Scopus to identify trials. Data Extraction and Synthesis Intention-to-treat and as-treated analyses were performed. The number needed to treat to prevent 1 distant metastasis at 10 years was calculated based on prognostic risk group. The analyses were conducted from January 5 to August 15, 2023. Main Outcomes and Measures The primary end point for this study was overall survival, defined as time to death or last follow-up from randomization. Secondary end points included biochemical recurrence, distant metastasis (DM), prostate cancer–specific mortality, and other-cause mortality. Results The median (IQR) age among the 10 266 male patients was 70 (65-74) years. Longer durations of ADT were associated with nonlinear improvement in relative benefits of DM, prostate cancer–specific mortality, and overall survival, with reduced estimated benefits beyond 9 to 12 months of ADT based on the end point. There was a near-linear increase in other-cause mortality associated with long-term ADT use (hazard ratio, 1.28; 95% CI, 1.09-1.50; P = .002 for 28 vs 0 months of ADT). The optimal ADT duration based on 10-year DM was 0, 6, 12 months, and undefined for patients with 1 intermediate-risk factor, 2 or more intermediate-risk factors, and National Comprehensive Cancer Network high-risk and very high-risk disease, respectively. Conclusions and Relevance The results of this meta-analysis suggest that, for men with localized prostate cancer treated with definitive radiotherapy and ADT, there are relative and absolute benefits from increasing durations of ADT that help provide individualized risk estimates.
Neurodevelopmental effects of genetic frontotemporal dementia mutations revealed by total intracranial volume differences
So, Isis , Bouzigues, Arabella , Russell, Lucy L. , Foster, Phoebe H. , Ferry‐Bolder, Eve , Swieten, John C. van, Jiskoot, Lize C, Laforce, Robert, Graff, Caroline , Galimberti, Daniela , Vandenberghe, Rik, Xiong, Chengjie , Sorbi, Sandro, Pasquier, Florence, Ducharme, Simon , Butler, Christopher , Ber, Isabelle Le, Masellis, Mario, Moreno, Fermín , Borroni, Barbara , Kolander, Tyler, Mester, Carly , Brushaber, Danielle , Kantarci, Kejal , Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam L. , Rosen, Howard J., Investigators, on behalf of Frontotemporal Dementia Prevention Initiative (FPI), Bocchetta, Martina , Jiskoot, Lize C. , Galimberti, Daniela , de Mendonça, Alexandre , Tartaglia, Maria Carmela , Rowe, James B , Synofzik, Matthis , Mester, Carly , Finger, Elizabeth C. , Kantarci, Kejal , Xiong, Chengjie , Russell, Lucy L , Bocchetta, Martina , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Borroni, Barbara , Swieten, John C. van , Seelaar, Harro , Sánchez‐Valle, Raquel , Laforce, Robert , Vandenberghe, Rik , Mendonça, Alexandre de , Tiraboschi, Pietro , Santana, Isabel , Gerhard, Alexander , Sorbi, Sandro , Otto, Markus , Pasquier, Florence , Ber, Isabelle Le , Rowe, James B. , Synofzik, Matthis , Rohrer, Jonathan D. , Boeve, Bradley F. , Investigators, on behalf of Frontotemporal Dementia Prevention Initiative (FPI)

Mayo Clinic

Journal of Alzheimer’s Disease | November 19, 2025 | Volume: 109 | Issue: 1 | Pages: 278-290

10.1177/13872877251393414 | PMID 41259271 Get It

Background Converging evidence hints at neurodevelopmental effects in people at risk of genetic frontotemporal dementia (FTD). Objective We investigated total intracranial volume (TIV), a neuroimaging marker of neurodevelopment, and years of education differences between adult mutation carriers and familial non-mutation carriers, as measures of the structural and functional neurodevelopmental effects of FTD-causing genetic mutations. Methods This cross-sectional cohort study, facilitated through the FTD Prevention Initiative (FPI), included 902 adult pathogenic mutation carriers of GRN , MAPT , or C9orf72 , and 532 familial non-carriers. ANCOVAs were computed to compare TIV and education between groups per gene. Pearson's correlations were used to examine associations between TIV and education. Results Mutation carriers (mean ± SD age = 50.0 ± 13.2 years, sex = 55% female, n ( GRN ) = 298, n( MAPT ) = 187, n ( C9orf72 ) = 417) were compared to familial non-carriers (age = 48.0 ± 12.9 years, sex = 58% female, n ( GRN ) = 201, n( MAPT ) = 114), n ( C9orf72 ) = 217). Consistent with prior findings in young adults, GRN carriers showed larger TIV, on average by 20531 mm 3 , compared to familial non-carriers (95% CI [85.4, 40977], p = 0.049, η 2 p = 0.008). Larger TIV correlated with higher years of education in GRN carriers (95% CI [0.01, 0.24], r (295) = 0.12, p = 0.03) and GRN non-carriers (95% CI [0.08, 0.34], r(198) = 0.21, p = 0.002). MAPT carriers demonstrated smaller TIV than non-carriers, on average by 29896 mm 3 (95% CI [–58248, −1545], p = 0.039, η 2 p = 0.02). Models with C9orf72 and education as outcome variables did not reveal significant differences. Conclusions In support of the neurodevelopmental hypothesis of FTD, GRN and MAPT mutations are linked to structural neurodevelopmental changes in TIV. Further research is needed to identify mechanisms underlying neurodevelopmental influences of FTD mutations and ascertain their suitability as intervention targets.